These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29228983)

  • 1. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.
    Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH
    Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
    Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
    J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.
    Winquist J; Abdurakhmanov E; Baraznenok V; Henderson I; Vrang L; Danielson UH
    Antiviral Res; 2013 Mar; 97(3):356-68. PubMed ID: 23305851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annexin A2 is involved in the formation of hepatitis C virus replication complex on the lipid raft.
    Saxena V; Lai CK; Chao TC; Jeng KS; Lai MM
    J Virol; 2012 Apr; 86(8):4139-50. PubMed ID: 22301157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current perspective of HCV NS5B inhibitors: a review.
    Patil VM; Gupta SP; Samanta S; Masand N
    Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
    Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.
    Wang H; Guo C; Chen BZ; Ji M
    Antiviral Res; 2015 Jan; 113():79-92. PubMed ID: 25449363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.
    McKercher G; Beaulieu PL; Lamarre D; LaPlante S; Lefebvre S; Pellerin C; Thauvette L; Kukolj G
    Nucleic Acids Res; 2004; 32(2):422-31. PubMed ID: 14739234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.
    Abdurakhmanov E; Øie Solbak S; Danielson UH
    Viruses; 2017 Jun; 9(6):. PubMed ID: 28621755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase.
    Zheng BZ; D'Andrea SV; Hanumegowda U; Knipe JO; Mosure K; Zhuo X; Lemm JA; Liu M; Rigat KL; Wang YK; Fang H; Poronsky C; Cutrone J; Wu DR; Arunachalam PN; Balapragalathan TJ; Arumugam A; Mathur A; Meanwell NA; Gao M; Roberts SB; Kadow JF
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3294-3300. PubMed ID: 28633899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.
    Beaulieu PL
    IDrugs; 2010 Dec; 13(12):938-48. PubMed ID: 21154154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
    Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
    Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.
    Yi G; Deval J; Fan B; Cai H; Soulard C; Ranjith-Kumar CT; Smith DB; Blatt L; Beigelman L; Kao CC
    Antimicrob Agents Chemother; 2012 Feb; 56(2):830-7. PubMed ID: 22143520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Rigat KL; Lu H; Wang YK; Argyrou A; Fanslau C; Beno B; Wang Y; Marcinkeviciene J; Ding M; Gentles RG; Gao M; Abell LM; Roberts SB
    J Biol Chem; 2014 Nov; 289(48):33456-68. PubMed ID: 25301950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
    Beaulieu PL
    Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.
    Wagner F; Thompson R; Kantaridis C; Simpson P; Troke PJ; Jagannatha S; Neelakantan S; Purohit VS; Hammond JL
    Hepatology; 2011 Jul; 54(1):50-9. PubMed ID: 21488067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
    Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
    J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
    Brown JA; Thorpe IF
    Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
    Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
    Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.